SEARCH

SEARCH BY CITATION

References

  • 1
    Lipsky BA, Berendt AR, Deery G et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis, 2004;39:885910.
  • 2
    Cierny G III, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res, 2003;414:724.
  • 3
    Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med, 1997;336:9991007.
  • 4
    Aragon-Sanchez J, Lazaro-Martinez JL, Quintana-Marrero Y, Hernandez-Herrero MJ, Garcia-Morales E, Cabrera-Galvan JJ, Beneit-Montesino JV. Are diabetic foot ulcers complicated by MRSA osteomyelitis associated with worse prognosis? Diabet Med, 2009;26:552555.
  • 5
    Hatzenbuehler J, Pulling TJ. Diagnosis and management of osteomyelitis. Am Fam Physician, 2011;84:10271033.
  • 6
    Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Disease Pharmacists. Am J Health-Syst Pharm, 2009;66:8298.
  • 7
    Product information. Vancomycin. New York, NY: Pfizer, Inc., December 2010.
  • 8
    Garazzino S, Aprato A, Baietto L et al. Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. Clin Pharmacokinet, 2008;47:793805.
  • 9
    Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant gram-positive bone and joint infections. Curr Med Res Opin, 2005;21:19231926.
  • 10
    Product information. Zyvox (linezolid). Peapack, NJ: Pharmacia & Upjohn, June 2010.
  • 11
    Senneville E, Legout L, Valette M et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther, 2006;28:11551163.
  • 12
    Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis, 2006;42:15781583.
  • 13
    Komatsu M, Takahata M, Sugawara M et al. Penetration of linezolid into rabbit intervertebral discs and surrounding tissues. Eur Spine J, 2010;19:21492155.
  • 14
    Metallidis S, Nikolaidis J, Lazaraki G et al. Penetration of linezolid into sternal bone of patients undergoing cardiopulmonary bypass surgery. Int J Antimicrob Agents, 2007;29:742744.
  • 15
    Traunmüller F, Schintler MV, Spendel S, Popovic M, Mauric O, Scharnaql E, Joukhadar C. Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections. Int J Antimicrob Agents, 2010;36:8486.
  • 16
    Kutscha F, Hebler U, Muhr G, Koller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother, 2003;47:39643966.
  • 17
    Lovering AM, Zhang J, Bannister GC, Lankester BJ, Brown JH, Narendra G, MacGowan AP. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother, 2002;50:7377.
  • 18
    Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother, 2002;50:747750.
  • 19
    Lu PL, Wang JT, Chen CJ, Chen WC, Chen TC, Hwang YC, Chang SC. Compassionate use of linezolid for adult Taiwanese patients with bone and joint infections. Chemotherapy, 2010;56:429435.
  • 20
    Legout L, Valette M, Dezeque H et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia. J Antimicrob Chemother, 2010;65:22242230.
  • 21
    Rao N, Hamilton CW. Efficacy and safety of linezolid for gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis, 2007;59:173179.
  • 22
    Aneziokoro CO, Cannon JP, Pachucki CT, Lentino JR. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother, 2005;17:643650.
  • 23
    Bassetti M, Vitale F, Melica G et al. Linezolid in the treatment of gram-positive prosthetic joint infections. J Antimicrob Chemother, 2005;55:387390.
  • 24
    Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis, 2004;38:521528.
  • 25
    Rao N, Ziran BH, Hall RA, Santa ER. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res, 2004;427:6771.
  • 26
    Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection, 2004;32:814.
  • 27
    Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc, 2004;79:11371144.
  • 28
    Product information. Cubicin (daptomycin). Lexington, MA: Cubist Pharmaceuticals, Inc., December 2010.
  • 29
    Rice DA, Mendez-Vigo L. Daptomycin in bone and joint infections: a review of the literature. Arch Orthop Trauma Surg, 2009;129:14951504.
  • 30
    Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother, 2000;44:29482953.
  • 31
    Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in creatine phosphokinase levels: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis, 2010;50:15681574.
  • 32
    Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med, 2006;355:653665.
  • 33
    Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outocmes when utilizing high-dose (>/= 8 mg/kg) daptomycin therapy. Ann Pharmacother, 2009;43:12111219.
  • 34
    Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother, 1989;33:689692.
  • 35
    Lalani T, Boucher HW, Cosgrove SE et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteremia. J Antimicrob Chemother, 2008;61:177182.
  • 36
    Burdette SD. Daptomycin for methicillin-resistant Staphylococcus aureus infections of the spine. Spine J, 2011;9:e5e8.
  • 37
    Rolston KV, Segreti J, Lamp KC, Friedrich LV. Cubist outcomes registry and experience (CORE) methodology. Am J Med, 2007;120:5455.
  • 38
    Lamp KC, Fridrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med, 2007;120:S13S20.
  • 39
    Gonzalez-Ruiz A, Beiras-Fernandez A, Lehmkuhl H, Seaton RA, Loeffler J, Chaves RL. Clinical experience with daptomycin in Europe: the first 2.5 years. J Antimicrob Chemother, 2011;66:912919.
  • 40
    Product information. Tygacil (tigecycline). Philadelphia, PA: Pfizer, Inc., January 2011.
  • 41
    Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy, 2006;26:10991110.
  • 42
    Pankey GA. Tigecycline. J Antimicrob Chemother, 2005;56:470480.
  • 43
    Barbour A, Schmidt S, Ma B, Schiefelbein L, Rand KH, Burkhardt O, Derendorf H. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet, 2009;48:575584.
  • 44
    Aksoy DY, Unal S. New antimicrobial agents for the treatment of gram-positive bacterial infections. Clin Microbiol Infect, 2008;14:411420.
  • 45
    Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis, 2006;43:518524.
  • 46
    Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother, 2011;66:19631971.
  • 47
    Yin LY, Lazzarini L, Li F, Stevens CM, Calhoun JH. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistance Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother, 2005;55:9951002.
  • 48
    Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue, and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother, 2006;58:12211229.
  • 49
    Breukink EJ, Visscher I, Humphrey PP et al. Evidence for a multivalent interaction between telavancin and membranebound lipid II. Paper presented at 46th annual interscience conference on antimicrobial agents and chemotherapy. San Francisco, CA: American Society for Microbiology, 2006 Sep.
  • 50
    Attwood RJ, LaPlante KL. Telavancin: a novel lipoglycopeptide antimicrobial agent. Am J Health-Syst Pharm, 2007;64:23352348.
  • 51
    King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration dependent anti-infective with multiple mechanisms of action against gram positive bacteria. J Antimicrob Chemother, 2004;53:797803.
  • 52
    Draghi DC, Benton BM, Cohen MA et al. In vitro activity of telavancin against enterococci: results of the 2004–2005 US surveillance initiative. Paper presented at 46th annual interscience conference on antimicrobial agents and chemotherapy. San Francisco, CA: American Society for Microbiology, 2006 Sep.
  • 53
    Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother, 2006;58:338343.
  • 54
    Pace JL, Krause K, Johnston D et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother, 2003;47:36023604.
  • 55
    Thornsberry C, Draghi DC, Benton BM et al. Baseline profile of telavancin activity against streptococci; results of the USA surveillance initiative. Paper presented at 46th annual interscience conference on antimicrobial agents and chemotherapy. San Francisco, CA: American Society for Microbiology, 2006 Sep.
  • 56
    Product information. Vibativ (telavancin). San Francisco, CA/Deerfield, IL: Theravance/Astellas, September 2009.
  • 57
    Yin LY, Calhoun JS, Thomas TS, Wirtz ED. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. J Antimicrob Chemother, 2009;63:357360.
  • 58
    Twilla JD, Gelfand MS, Cleveland KO, Usery JB. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. J Antimicrob Chemother, 2011;66:26752677.
  • 59
    Product information. Teflaro (ceftaroline). St. Louis, MO: Forest Pharmaceuticals, Inc., April 2011.
  • 60
    Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis, 2011;52:11561163.
  • 61
    Steed ME, Rybak MJ. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy, 2010;30:375389.
  • 62
    Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother, 2007;51:36123616.
  • 63
    Jacqueline C, Amader G, Caillon J et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother, 2010;65:17491752.
  • 64
    Higgins DL, Chang R, Debabov DV et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother, 2005;49:11271134.
  • 65
    MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother, 2003;51:ii17ii25.
  • 66
    Traunmuller F, Schintler MV, Metzler J et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother, 2010;65:12521257.
  • 67
    Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother, 2004;48:6368.
  • 68
    Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/pharmacodynamic profile for tigecycline – a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis, 2005;52:165171.
  • 69
    MacGowan AP, Noel AR, Tomaselli S, Elliot HC, Bowker KE. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother, 2011;55:867873.
  • 70
    Zhanel GG, Rossnagel E, Nichol K et al. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus, and vancomycin-resistant S. aureus using an in vitro model. J Antimicrob Chemother, 2011;66:13011305.